Literature DB >> 15837794

Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes.

Axel Thiefes1, Sabine Wolter, J Frederic Mushinski, Elke Hoffmann, Oliver Dittrich-Breiholz, Nadine Graue, Anneke Dörrie, Heike Schneider, Dagmar Wirth, Bruno Luckow, Klaus Resch, Michael Kracht.   

Abstract

The inflammatory response is characterized by the induction (or repression) of hundreds of genes. The activity of many of these genes is controlled by MAPKs and the IkappaB kinase-NFkappaB pathway. To reveal the effects of blocking these pathways simultaneously, fibroblasts were infected with retroviruses encoding TAK1K63W, an inactive mutant of the protein kinase TAK1. Expression of this protein inhibited tumor necrosis factor (TNF)-induced activation of NFkappaB, JNK, and p38 MAPK and sensitized the cells to TNF-induced apoptosis. 23 different microarray experiments were used to analyze the expression of >7000 genes in these cells. We identified 518 genes that were regulated by TNF in both TAK1K63W-expressing cells and control cells, 37 genes induced by TNF only when TAK1K63W was present, and 48 TNF-induced genes that were suppressed by TAK1K63W. The TNF-inducible genes that were most strongly suppressed by TAK1K63W, ccl2, ccl7, ccl5, cxcl1, cxcl5, cxcl10, saa3, and slpi also had much lower basal levels of expression, indicating that TAK1 also played a role in their normal expression. Chromatin immunoprecipitation studies on four of these genes suggested that inactivation of TAK1 activity led to direct suppression of expression at the transcriptional level because of impaired recruitment of RNA polymerase II to their promoters. ccl2 induction by TNF or interleukin-1 was also suppressed in cells that expressed TAK1 antisense RNA or that were genetically deficient in JNK1/2 or p65 NFkappaB. These data suggest that regulation of the expression of a selected group of inflammation-related genes is funneled through TAK1, making it a potentially useful target for more specific anti-inflammatory drug development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837794     DOI: 10.1074/jbc.M411657200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

2.  Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma.

Authors:  Sarah H Beachy; Masahiro Onozawa; Yang Jo Chung; Chris Slape; Sven Bilke; Princy Francis; Marbin Pineda; Robert L Walker; Paul Meltzer; Peter D Aplan
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

3.  The Yersinia enterocolitica effector YopP inhibits host cell signalling by inactivating the protein kinase TAK1 in the IL-1 signalling pathway.

Authors:  Axel Thiefes; Alexander Wolf; Anneke Doerrie; Guntram A Grassl; Kunihiro Matsumoto; Ingo Autenrieth; Erwin Bohn; Hiroaki Sakurai; Rainer Niedenthal; Klaus Resch; Michael Kracht
Journal:  EMBO Rep       Date:  2006-07-14       Impact factor: 8.807

4.  Phosphorylation of NF-kappaB p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-specific proteasomal elimination.

Authors:  Hui Geng; Tobias Wittwer; Oliver Dittrich-Breiholz; Michael Kracht; Michael Lienhard Schmitz
Journal:  EMBO Rep       Date:  2009-03-06       Impact factor: 8.807

5.  Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

Authors:  Davide Melisi; Qianghua Xia; Genni Paradiso; Jianhua Ling; Tania Moccia; Carmine Carbone; Alfredo Budillon; James L Abbruzzese; Paul J Chiao
Journal:  J Natl Cancer Inst       Date:  2011-07-08       Impact factor: 13.506

6.  An essential role for TAK1 in the contact hypersensitivity response.

Authors:  Yan G Zhao; Yunqi Wang; Weidong Hao; Yisong Y Wan
Journal:  Cell Mol Immunol       Date:  2011-05-09       Impact factor: 11.530

7.  Increased apoptosis and browning of TAK1-deficient adipocytes protects against obesity.

Authors:  Antonia Sassmann-Schweda; Pratibha Singh; Cong Tang; Astrid Wietelmann; Nina Wettschureck; Stefan Offermanns
Journal:  JCI Insight       Date:  2016-05-19

8.  Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected].

Authors:  Wendy L Thompson; Linda J Van Eldik
Journal:  Brain Res       Date:  2009-07-03       Impact factor: 3.252

9.  c-Jun controls histone modifications, NF-kappaB recruitment, and RNA polymerase II function to activate the ccl2 gene.

Authors:  Sabine Wolter; Anneke Doerrie; Axel Weber; Heike Schneider; Elke Hoffmann; Juliane von der Ohe; Latifa Bakiri; Erwin F Wagner; Klaus Resch; Michael Kracht
Journal:  Mol Cell Biol       Date:  2008-04-28       Impact factor: 4.272

10.  Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide.

Authors:  H E Barksby; C J Nile; K M Jaedicke; J J Taylor; P M Preshaw
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.